Siltuximab 是一种anti-IL-6(interleukin-6) 单克隆抗体，具有抗肿瘤活性。Siltuximab 可用于多中心性巨大淋巴结增生症 (MCD) 和 COVID-19 的研究。
| 生物活性 | Siltuximab is an anti-IL-6(interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research[1][2][3]. |
体内研究
(In Vivo) | Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) inhibits the growth of lung cancer cells in xenograft mouse model[1].
Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model[4].
| Animal Model: | Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; 10 mg/kg; 3 times per week | | Result: | Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells.
Repressed PY-STAT3 levels in H1650 cells.
Inhibited the growth of tumors with H322 and CAF cells.
Inhibited the growth of tumors with H1650 and CAF cells. |
| Animal Model: | Female NOD-SCID mice with MCF-7 tumor[4] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks | | Result: | Blocked MCF-7 engraftment, induced regressions in 90% of tumors. |
|
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com